Integrin α7 knockdown suppresses cell proliferation, migration, invasion and EMT in hepatocellular carcinoma

Wu,Zhiyong; Kong,Xiaoyu; Wang,Zhihui

doi:10.3892/etm.2021.9740

Integrin α7 knockdown suppresses cell proliferation, migration, invasion and EMT in hepatocellular carcinoma

Authors:
- Zhiyong Wu
- Xiaoyu Kong
- Zhihui Wang
View Affiliations

Affiliations: Department of General Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China
Published online on: February 1, 2021 https://doi.org/10.3892/etm.2021.9740
Article Number: 309
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effects of integrin α7 (ITGA7) on regulating hepatocellular carcinoma (HCC) progression and endothelial‑mesenchymal transition (EMT). ITGA7 mRNA and protein expression in human normal liver epithelial cells and HCC cell lines were determined by reverse transcription‑quantitative PCR (RT‑qPCR) and western blotting. ITGA7 small interfering RNA [siRNA; ITGA7‑knockdown (KD) group] and nonsense siRNA (control group) were transfected into Huh7 cells and SNU449 cells, respectively. ITGA7 mRNA and protein expression (RT‑qPCR and western blotting, respectively), cell proliferation (Cell Counting Kit‑8 assay), apoptosis (annexin V/propidium iodide assay), migration (wound scratch assay) and invasion (Transwell assay) were then detetected. E‑cadherin, α‑smooth muscle actin (α‑SMA), vimentin and V‑cadherin levels (RT‑qPCR and western blotting) were also assessed. ITGA7 mRNA and protein expression levels were increased in Li7, Huh7, SKHEP1 and SNU449 cells compared with THLE‑3 cells. Following transfection, ITGA7 mRNA and protein expression was lower in the ITGA7‑KD group compared with that in the control group in both Huh7 and SNU449 cells, indicating successful transfection. In the ITGA7‑KD group, cell proliferation decreased at 48 and 72 h, cell apoptosis rates increased at 48 h, cell migration rate was reduced at 24 h and cell invasion decreased at 24 h compared with the control group. Additionally, increased E‑cadherin but decreased α‑SMA, vimentin and V‑cadherin mRNA and protein expression levels were observed in the ITGA7‑KD group compared with the control group at 24 h. In conclusion, ITGA7 knockdown suppressed HCC progression and inhibited EMT in HCC in vitro, implying that ITGA7 might be a novel treatment target for HCC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
2	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012.PubMed/NCBI View Article : Google Scholar
3	Desgrosellier JS and Cheresh DA: Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer. 10:9–22. 2010.PubMed/NCBI View Article : Google Scholar
4	Carrasco-Garcia E, Auzmendi-Iriarte J and Matheu A: Integrin α7: A novel promising target in glioblastoma stem cells. Stem Cell Investig. 5(2)2018.PubMed/NCBI View Article : Google Scholar
5	Ming XY, Fu L, Zhang LY, Qin YR, Cao TT, Chan KW, Ma S, Xie D and Guan XY: Integrin α7 is a functional cancer stem cell surface marker in oesophageal squamous cell carcinoma. Nat Commun. 7(13568)2016.PubMed/NCBI View Article : Google Scholar
6	Hsu YL, Hung JY, Liang YY, Lin YS, Tsai MJ, Chou SH, Lu CY and Kuo PL: S100P interacts with integrin α7 and increases cancer cell migration and invasion in lung cancer. Oncotarget. 6:29585–29598. 2015.PubMed/NCBI View Article : Google Scholar
7	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
8	Hynes RO: Integrins: Bidirectional, allosteric signaling machines. Cell. 110:673–687. 2002.PubMed/NCBI View Article : Google Scholar
9	Tan LZ, Song Y, Nelson J, Yu YP and Luo JH: Integrin α7 binds tissue inhibitor of metalloproteinase 3 to suppress growth of prostate cancer cells. Am J Pathol. 183:831–840. 2013.PubMed/NCBI View Article : Google Scholar
10	Nunes AM, Barraza-Flores P, Smith CR and Burkin DJ: Integrin α7: A major driver and therapeutic target for glioblastoma malignancy. Stem Cell Investig. 4(97)2017.PubMed/NCBI View Article : Google Scholar
11	Burkin DJ and Fontelonga TM: Mesothelioma cells breaking bad: Loss of integrin α7 promotes cell motility and poor clinical outcomes in patients. J Pathol. 237:282–284. 2015.PubMed/NCBI View Article : Google Scholar
12	Haas TL, Sciuto MR, Brunetto L, Valvo C, Signore M, Fiori ME, di Martino S, Giannetti S, Morgante L, Boe A, et al: Integrin α7 Is a Functional Marker and Potential Therapeutic Target in Glioblastoma. Cell Stem Cell. 21:35–50.e9. 2017.PubMed/NCBI View Article : Google Scholar
13	Zhu ZH, Yu YP, Zheng ZL, Song Y, Xiang GS, Nelson J, Michalopoulos G and Luo JH: Integrin alpha 7 interacts with high temperature requirement A2 (HtrA2) to induce prostate cancer cell death. Am J Pathol. 177:1176–1186. 2010.PubMed/NCBI View Article : Google Scholar
14	Bai X, Gao C, Zhang L and Yang S: Integrin α7 high expression correlates with deteriorative tumor features and worse overall survival, and its knockdown inhibits cell proliferation and invasion but increases apoptosis in breast cancer. J Clin Lab Anal. 33(e22979)2019.PubMed/NCBI View Article : Google Scholar
15	Su Y, Guan XQ, Liu FQ and Wang YL: The effects of MIBG on the invasive properties of HepG2 hepatocellular carcinoma cells. Int J Mol Med. 34:842–848. 2014.PubMed/NCBI View Article : Google Scholar
16	Ren B, Yu YP, Tseng GC, Wu C, Chen K, Rao UN, Nelson J, Michalopoulos GK and Luo JH: Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma. J Natl Cancer Inst. 99:868–880. 2007.PubMed/NCBI View Article : Google Scholar
17	Gyuris J, Golemis E, Chertkov H and Brent R: Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell. 75:791–803. 1993.PubMed/NCBI View Article : Google Scholar
18	Hannon GJ, Casso D and Beach D: KAP: A dual specificity phosphatase that interacts with cyclin-dependent kinases. Proc Natl Acad Sci USA. 91:1731–1735. 1994.PubMed/NCBI View Article : Google Scholar
19	Kawashima T, Hirose K, Satoh T, Kaneko A, Ikeda Y, Kaziro Y, Nosaka T and Kitamura T: MgcRacGAP is involved in the control of growth and differentiation of hematopoietic cells. Blood. 96:2116–2124. 2000.PubMed/NCBI
20	Brabletz T: EMT and MET in metastasis: Where are the cancer stem cells? Cancer Cell. 22:699–701. 2012.PubMed/NCBI View Article : Google Scholar
21	Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008.PubMed/NCBI View Article : Google Scholar
22	Zou J, Li H, Huang Q, Liu X, Qi X, Wang Y, Lu L and Liu Z: Dopamine-induced SULT1A3/4 promotes EMT and cancer stemness in hepatocellular carcinoma. Tumour Biol. 39(1010428317719272)2017.PubMed/NCBI View Article : Google Scholar
23	Santamaria PG, Moreno-Bueno G, Portillo F and Cano A: EMT: Present and future in clinical oncology. Mol Oncol. 11:718–738. 2017.PubMed/NCBI View Article : Google Scholar
24	Nistico P: Bissell MJandRadisky DC: Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harb Perspect Biol. 4(a011908)2012.PubMed/NCBI View Article : Google Scholar
25	Gaianigo N: Melisi D and Carbone C: EMT and Treatment Resistance in Pancreatic Cancer. Cancers (Basel). 9(122)2017.PubMed/NCBI View Article : Google Scholar